A multicentre, randomised, open-label, parallel-group trial to study the safety and non-inferiority of a new therapeutic strategy (the fuster-cnicferrer cardiovascular polypill) versus usual care on ldlc and blood pressure reduction in patients with atherothrombotic cardiovascular disease: the apolo trial